Peddling life cycle management
This article was originally published in Scrip
In the early days, even before anyone had a name for it, life cycle management was a defensive strategy, an end-of-life rescue therapy in which delivery systems and reformulations gave drugs an extra few years before they were retired to generic pastures. But as Scrip’s new "Lessons in lifecycle management" analysis points out, life cycle management can is now about maximising the health of products throughout their lifetime, and not just about their longevity.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.